Skip to main content
Prof. Dr. Marieta Toma
Johann Saba, UKB

News categories: Focus

Welcoming Marieta Toma to ImmunoSensation

We are thrilled to welcome Prof. Dr. Marieta Toma Deputy Director of the Institute of Pathology at the University Hospital Bonn as a new member of the ImmunoSensation2 Cluster of Excellence. Marieta Toma is a leading expert in translational research with particular interest in establishing patient-derived models for cancer research.

Research focus: From patient-derived primary cell lines to organoids

The working group of Marieta Toma employs patient-derived primary cell models and organoid systems, that are used to study the complex biology of solid malignant tumors. Marieta Toma’s research focuses on establishing applicable models and identifying disease biomarkers for cancer research. Her expertise ranges from a variety of diseases, with particular interest kidney tumors, bile duct carcinomas, and brain metastases.

A key aspect of Marieta Toma’s work involves developing patient-derived models that closely mimic the tumor microenvironment. These advanced systems allow researchers to investigate the molecular mechanisms that influence disease development and progression. In addition, Marieta Toma’s group uses advanced techniques such as microscopy, pathologic diagnostics, spatial biology, and image analysis tools to uncover the complex interplay between different environmental factors that impact tumor development. 

Collaborations within the Cluster

Marieta Toma’s collaboration with the ImmunoSensation2 scientists offers the potential to integrate advanced immunological profiling with her state-of-the-art organoid models, paving the way for impactful discoveries.

Looking ahead

In the future, Marieta Toma aims to further unravel the immunological dynamics within solid tumors. Her future research will explore how the complex interactions within tissue influence tumor progression and resistance to therapy, ultimately aiming to improve therapeutic outcomes for patients with aggressive cancers.

Marieta Toma shares her enthusiasm for joining the Cluster: “The integration of patient-derived models with immunological research offers unprecedented opportunities to bridge the gap between basic science and clinical application. I am excited to contribute to ImmunoSensation2’s efforts to better understand and treat immune-related diseases.”

We warmly welcome Marieta Toma to ImmunoSensation and are excited about the innovative contributions she will bring to our Cluster.

 

Contact:

Prof. Dr. Marieta Toma

Institute of Pathology

University Hospital Bonn

Email: marieta.toma@ukbonn.de 

Related news

Prof. Dr. Jörg Wenzel

News categories: Focus

Welcoming Jörg Wenzel to ImmunoSensation

We are delighted to welcome Prof. Dr. Jörg Wenzel from the Center for Skin Diseases at the University Hospital Bonn to the Cluster of Excellence ImmunoSensation2. Jörg Wenzel is a dermatologist and physician-scientist with extensive expertise in inflammatory skin diseases and cutaneous immunology.
View entry
Prof. Dr. Christian Bode

News categories: Focus

Welcoming Christian Bode to ImmunoSensation

We are delighted to welcome Prof. Dr. Christian Bode from the Department of Anesthesiology and Intensive Care Medicine at the University Hospital Bonn to the Cluster of Excellence ImmunoSensation2. Christian Bode is a physician-scientist whose work focuses on the intersection of immunology and critical care. His research centers around understanding the immune responses in patients undergoing major surgery, acute lung failure (ARDS), or sepsis.
View entry
Prof. Dr. Oliver Brüstle

News categories: Focus

Welcoming Oliver Brüstle to ImmunoSensation

We are delighted to welcome Prof. Dr. Oliver Brüstle, head of the Institute of Reconstructive Neurobiology at the University Hospital Bonn, to the Cluster of Excellence ImmunoSensation2. Oliver Brüstle is a leading expert in stem cell research and regenerative medicine, bringing an exciting new dimension to the Cluster's interdisciplinary focus on immunity in health and disease.
View entry

Back to the news overview